Filippo Berio recall exposes allergen labelling risk

Allergen control remains a live manufacturing risk. Filippo Berio UK has recalled Hot Chilli Pesto after fish was not declared on the product label.


IN Brief:

  • Filippo Berio UK has recalled 190g jars of Hot Chilli Pesto over undeclared fish.
  • The recall covers batch LR319, with a best-before date of 15 May 2028.
  • The alert underlines the need for robust label verification, allergen controls, and supplier-specification checks.

Filippo Berio UK has recalled 190g jars of Hot Chilli Pesto because the product contains fish that is not declared on the label.

The Food Standards Agency has issued an allergy alert covering batch code LR319, with a best-before date of 15 May 2028. The undeclared fish presents a possible health risk for anyone with an allergy to fish.

The company is recalling the affected product from customers and has issued a point-of-sale notice. Consumers who have bought the product and have a fish allergy have been advised not to eat it and to return it to the store of purchase for a full refund.

Although the affected batch is narrow, the recall points to a persistent control risk in food manufacturing. Allergen recalls can originate in artwork errors, supplier specification changes, recipe updates, cross-contact, ingredient substitution, compound ingredient changes, or a failure to reconcile finished-pack labels with current formulation data.

Products such as pesto can involve several allergen-sensitive inputs, including cheese, nuts, fish-derived ingredients, herbs, oils, spices, and savoury components. The control burden extends beyond one raw material and into the way recipes, specifications, and labels are managed across the full product lifecycle.

Label accuracy is not only a technical services function. It sits across procurement, NPD, production, quality, regulatory, packaging, and artwork approval. A supplied ingredient change or formulation update that does not move cleanly through that chain can become a recall after product has entered distribution.

Long shelf-life products create an additional containment challenge. Ambient sauces, condiments, pestos, pastes, and similar products can remain in warehouses, stores, and domestic cupboards for extended periods. Batch traceability, retailer coordination, customer notification, and clear recall notices therefore become central to limiting exposure.

Reformulation activity is also increasing across the sector as brands adjust preservatives, colours, allergens, cost-sensitive ingredients, nutritional profiles, country-of-origin declarations, and sustainability claims. Each change creates another point where label and recipe control must stay aligned.

That pressure is already visible in ALDI US expanding private-label ingredient restrictions, which will push suppliers to reformulate across colours, preservatives, sweeteners, and other additives by 2027. The Filippo Berio recall is a separate incident, but it sits in the same operational reality: ingredient systems and labels have to move together.

Compound ingredients remain a common weak point. Where manufacturers use sauces, flavour blends, pastes, seasonings, or semi-processed components, finished-product allergen control depends on supplier declarations and change-management discipline. A supplier’s formulation change can become the brand owner’s recall if the information does not move quickly and accurately through internal systems.

Digital specifications, automated artwork checks, barcode verification, line clearance controls, and product-release protocols can reduce risk, but they depend on accurate master data and clear ownership. In many plants, the vulnerable point is still handover: between development and production, between technical and packaging, or between supplier notification and internal approval.

The recall is therefore a reminder of how little tolerance there is for weak links between formulation, specification, artwork, and finished-pack release. Allergen control is only as strong as the system that connects those functions.


Stories for you


  • EPAX Cetoleic 2040 lowers LDL in clinical trial

    EPAX Cetoleic 2040 lowers LDL in clinical trial

    EPAX Cetoleic 2040 reduced LDL-cholesterol by 7% after eight weeks in a randomised clinical trial of overweight and obese adults, adding human data to the emerging category of marine long-chain monounsaturated fatty acids.


  • T. Hasegawa targets dairy-free flavour gap

    T. Hasegawa targets dairy-free flavour gap

    T. Hasegawa USA has launched HASEMILK, a powdered dairy-free flavour technology designed to recreate milk taste, aroma, and mouthfeel in plant-based beverages, bakery, desserts, sauces, and dry mixes.